Abstract
Long non-coding RNAs (lncRNAs) are key regulators in the pathophysiology of gastric cancer, and lncRNAs have been regarded as potential biomarkers and therapeutic targets for gastric cancer. The present study performed the WGCNA analysis of the GSE70880 dataset and aimed to identify novel lncRNAs associated with gastric cancer progression. Based on the WGCNA, the lncRNAs and mRNA co-expression network were constructed. A total of four modules were identified and the eigengenes in different modules were involved in various key signaling pathways. Furthermore, the co-expression networks were constructed between the lncRNAs and mRNA; this leads to the identification of 6 modules, which participated in various cellular pathways. The survival analysis showed that high expression of CCDC144NL antisense RNA 1 (CCDC144NL-AS1) and LINC01614 was positively correlated with the poor prognosis of patients with gastric cancer. The in vitro validation results showed that CCDC144NL-AS1 and LINC01614 were both up-regulated in the gastric cancer cells. Silence of CCDC144NL-AS1 and LINC01614 both significantly suppressed the cell proliferation and migration of gastric cancer cells, and also promoted the chemosensitivity of gastric cancer cells to 5-fluorouracil. Collectively, our results suggested that the newly identified two lncRNAs (CCDC144NL-AS1 and LINC01614) may act as oncogenes in gastric cancer.
Highlights
Gastric cancer represents one of the most common human malignancies, and the occurrence of gastric cancer is region dependent with about 60% of the cases are found in developing regions [1, 2]
Ren et al, performed the weighted gene co-expression network analysis (WGCNA), and the analysis revealed ILF3-AS1 acted as a ceRNA to regulate polypyrimidine tract binding protein 1 by repressing miR-29a expression in gastric cancer [14]
The differentially expressed mRNAs and Long non-coding RNAs (lncRNAs) were further subjected to GSEA Gene Ontology (GO) and KEGG analysis
Summary
Gastric cancer represents one of the most common human malignancies, and the occurrence of gastric cancer is region dependent with about 60% of the cases are found in developing regions [1, 2]. For the treatment of gastric cancer surgical resection is the key treatment for gastric cancer, while the CCDC144NL-AS1 and LINC01614 and Gastric Cancer five-year overall survival of gastric cancer patients after surgical treatment depends on the tumor stages with ~90% in early-stage and ~20% in advanced stage gastric cancer patients [3] In these patients diagnosed at an advanced stage, chemotherapy instead of surgical resection is considered for alleviating the symptoms in patients, chemotherapy only exhibits a modest beneficial effect on patients with metastatic patients, and chemotherapy has been largely limited chemoresistance [4, 5]. Further exploration into the mechanisms underlying gastric cancer progression may be helpful for us to develop novel strategies, to improve the clinical outcomes of gastric cancer patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
